Low expression of HER2 protein in breast cancer is biologically significant

Journal of Pathology

Volumn 210, Issue 3, 2006, Pages 358-362

  Tovey, S M ^a   Reeves, J R ^a   Stanton, P ^a   Ozanne, B W ^b   Bartlett, J M S ^a   Cooke, T G ^a  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

^b UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

EGFR; HER2; HER3; HER4; Radioimmunohistochemistry

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR 3; EPIDERMAL GROWTH FACTOR RECEPTOR 4; ESTROGEN RECEPTOR;

AGED; ARTICLE; BREAST CANCER; CANCER GRADING; CANCER MORTALITY; CANCER PATIENT; CANCER SURVIVAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG APPROVAL; DRUG TARGETING; FLUORESCENCE IN SITU HYBRIDIZATION; GENE OVEREXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; ISOTOPE LABELING; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; PROTEIN FAMILY; QUANTITATIVE ANALYSIS; REGULATORY MECHANISM;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, ERBB-1; HUMANS; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; RADIOCHEMISTRY; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2; RECEPTOR, ERBB-3; SURVIVAL ANALYSIS;

EID: 33750521806     PISSN: 00223417     EISSN: 10969896     Source Type: Journal    
DOI: 10.1002/path.2057     Document Type: Article

References (14)

1. Ross JS, Fletcher JA. The HER-2/neu oncogene in breast cancer: prognostic factor, predictive factor, and target for therapy. Stem Cells 1998;16:413-428.
2. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, Goldhirsch A, Untch M, Smith I, et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 2005;353:1659-1672.
3. Romond EH, Perez EA, Bryant J, Suman VJ, Geyer CE Jr, Davidson NE, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 2005;353:1673-1684.
4. Reeves JR, Going JJ, Smith G, Cooke TG, Ozanne BW, Stanton PD. Quantitative radioimmunohistochemical measurements of p185(erbB-2) in frozen tissue sections. J Histochem Cytochem 1996;44:1251-1259.
5. Bartlett JM, Going JJ, Mallon EA, Watters AD, Reeves JR, Stanton P, et al. Evaluating HER2 amplification and overexpression in breast cancer. J Pathol 2001;195:422-428.
6. Robertson KW, Reeves JR, Smith G, Keith WN, Ozanne BW, Cooke TG, et al. Quantitative estimation of epidermal growth factor receptor and c-erbB-2 in human breast cancer. Cancer Res 1996;56:3823-3830.
7. Witton CJ, Reeves JR, Going JJ, Cooke TG, Bartlett JM. Expression of the HER1-4 family of receptor tyrosine, kinases in breast cancer. J Pathol 2003;200:290-297.
8. Cooke T, Reeves J, Lannigan A, Stanton P. The value of the human epidermal growth factor receptor-2 (HER2) as a prognostic marker. Eur J Cancer 2001;37(Suppl 1):3-10.
9. Koscielny S, Terrier P, Daver A, Wafflart J, Goussard J, Ricolleau G, et al. Quantitative determination of c-erbB-2 in human breast tumours: potential prognostic significance of low values. Eur J Cancer 1998;34:476-481.
10. Yarden Y. Biology of HER2 and its importance in breast cancer. Oncology 2001;61(Suppl 2):1-13.
11. Tovey SM, Witton CJ, Bartlett JM, Stanton PD, Reeves JR, Cooke TG. Outcome and human epidermal growth factor receptor (HER) 1-4 status in invasive breast carcinomas with proliferation indices evaluated by bromodeoxyuridine, labelling. Breast Cancer Res 2004;6:R246-R251.
12. Tovey SM, Dunne B, Forsyth A, Witton CJ, Cooke TG, Bartlett JM. Can molecular markers predict when to implement treatment with aromatase inhibitors in invasive breast cancer? Clin Cancer Res 2005;11:4835-4842.
13. Newby JC, Johnston SR, Smith IE, Dowsett M. Expression of epidermal growth factor receptor and c-erbB2 during the development of tamoxifen resistance in human breast cancer. Clin Cancer Res 1997;3:1643-1651.
14. Sharma AK, Horgan K, Douglas-Jones A, McClelland R, Gee J, Nicholson R. Dual immunocytochemical analysis of oestrogen and epidermal growth factor receptors in human breast cancer. Br J Cancer 1994;69:1032-1037.